194 related articles for article (PubMed ID: 35336877)
1. Opposing Effects of Prior Infection versus Prior Vaccination on Vaccine Immunogenicity against Influenza A(H3N2) Viruses.
Fox A; Carolan L; Leung V; Phuong HVM; Khvorov A; Auladell M; Tseng YY; Thai PQ; Barr I; Subbarao K; Mai LTQ; van Doorn HR; Sullivan SG
Viruses; 2022 Feb; 14(3):. PubMed ID: 35336877
[TBL] [Abstract][Full Text] [Related]
2. Influenza virus infection history shapes antibody responses to influenza vaccination.
Auladell M; Phuong HVM; Mai LTQ; Tseng YY; Carolan L; Wilks S; Thai PQ; Price D; Duong NT; Hang NLK; Thanh LT; Thuong NTH; Huong TTK; Diep NTN; Bich VTN; Khvorov A; Hensen L; Duong TN; Kedzierska K; Anh DD; Wertheim H; Boyd SD; Good-Jacobson KL; Smith D; Barr I; Sullivan S; van Doorn HR; Fox A
Nat Med; 2022 Feb; 28(2):363-372. PubMed ID: 35177857
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial to assess immunogenicity of high-dose, adjuvanted, and recombinant influenza vaccines against cell-grown A(H3N2) viruses in adults 65 to 74 years, 2017-2018.
Belongia EA; Levine MZ; Olaiya O; Gross FL; King JP; Flannery B; McLean HQ
Vaccine; 2020 Mar; 38(15):3121-3128. PubMed ID: 32145994
[TBL] [Abstract][Full Text] [Related]
4. Influenza A(H3N2) Antibody Responses to Standard-Dose Versus Enhanced Influenza Vaccine Immunogenicity in Older Adults and Prior Season's Vaccine Status.
Zhong S; Ng TWY; Skowronski DM; Iuliano AD; Leung NHL; Perera RAPM; Ho F; Fang VJ; Tam YH; Ip DKM; Havers FG; Fry AM; Aziz-Baumgartner E; Barr IG; Peiris M; Thompson MG; Cowling BJ
J Infect Dis; 2024 May; 229(5):1451-1459. PubMed ID: 37950884
[TBL] [Abstract][Full Text] [Related]
5. Effects of Repeated Annual Inactivated Influenza Vaccination among Healthcare Personnel on Serum Hemagglutinin Inhibition Antibody Response to A/Perth/16/2009 (H3N2)-like virus during 2010-11.
Thompson MG; Naleway A; Fry AM; Ball S; Spencer SM; Reynolds S; Bozeman S; Levine M; Katz JM; Gaglani M
Vaccine; 2016 Feb; 34(7):981-8. PubMed ID: 26813801
[TBL] [Abstract][Full Text] [Related]
6. Comparison of immunogenicity between candidate influenza A(H3N2) virus vaccine strains in Japan: A randomized controlled trial using a monovalent vaccine of A/Saitama/103/2014 (CEXP-002) and A/Hong Kong/4801/2014 (X-263).
Kase T; Inoue M; Morikawa S; Kumashiro H; Hiroi S; Nakata K; Ito K; Ishibashi M; Tsuru T; Irie S; Maeda A; Ohfuji S; Fukushima W; Hirota Y
Vaccine; 2020 Sep; 38(42):6524-6532. PubMed ID: 32873406
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis.
Ruiz-Palacios GM; Leroux-Roels G; Beran J; Devaster JM; Esen M; Launay O; McElhaney JE; van Essen GA; Benoit A; Claeys C; Dewé W; Durand C; Duval X; Falsey AR; Feldman G; Galtier F; Gervais P; Hwang SJ; McNeil S; Richardus JH; Trofa A; Oostvogels L;
Hum Vaccin Immunother; 2016 Dec; 12(12):3043-3055. PubMed ID: 27690762
[TBL] [Abstract][Full Text] [Related]
8. An updated influenza A(H3N2) vaccine generates limited antibody responses to previously encountered antigens in children.
Florek KR; Campos LM; Braun KM; McLean HQ; King JP; Flannery B; Belongia EA; Friedrich TC
Vaccine; 2018 Jan; 36(5):758-764. PubMed ID: 29249543
[TBL] [Abstract][Full Text] [Related]
9. Impact of Immune Priming, Vaccination, and Infection on Influenza A(H3N2) Antibody Landscapes in Children.
Hinojosa M; Shepard SS; Chung JR; King JP; McLean HQ; Flannery B; Belongia EA; Levine MZ
J Infect Dis; 2021 Aug; 224(3):469-480. PubMed ID: 33090202
[TBL] [Abstract][Full Text] [Related]
10. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.
Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350
[TBL] [Abstract][Full Text] [Related]
11. Impact of prior vaccination on antibody response and influenza-like illness among Australian healthcare workers after influenza vaccination in 2016.
Leung VKY; Fox A; Carolan LA; Aban M; Laurie KL; Druce J; Deng YM; Slavin MA; Marshall C; Sullivan SG
Vaccine; 2021 Jun; 39(24):3270-3278. PubMed ID: 33985853
[TBL] [Abstract][Full Text] [Related]
12. Trivalent inactivated influenza vaccine response and immunogenicity assessment after one week and three months in repeatedly vaccinated adults.
Tawfik A; Kawaguchi T; Takahashi M; Setoh K; Yamaguchi I; Tabara Y; Van Steen K; Sakuntabhai A; Matsuda F
Expert Rev Vaccines; 2023; 22(1):826-838. PubMed ID: 37747798
[TBL] [Abstract][Full Text] [Related]
13. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
14. The effect of age and recent influenza vaccination history on the immunogenicity and efficacy of 2009-10 seasonal trivalent inactivated influenza vaccination in children.
Ng S; Ip DK; Fang VJ; Chan KH; Chiu SS; Leung GM; Peiris JS; Cowling BJ
PLoS One; 2013; 8(3):e59077. PubMed ID: 23554974
[TBL] [Abstract][Full Text] [Related]
15. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.
Ansaldi F; Canepa P; Ceravolo A; Valle L; de Florentiis D; Oomen R; Vogel FR; Denis M; Samson SI; Icardi G
Vaccine; 2012 Apr; 30(18):2908-13. PubMed ID: 22342501
[TBL] [Abstract][Full Text] [Related]
16. Serologic response to sequential vaccination with enhanced influenza vaccines: Open label randomized trial among adults aged 65-74 years.
McLean HQ; Levine MZ; King JP; Flannery B; Belongia EA
Vaccine; 2021 Dec; 39(49):7146-7152. PubMed ID: 34774360
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of seasonal inactivated influenza and inactivated polio vaccines among children in Senegal: Results from a cluster-randomized trial.
Niang M; Deming ME; Goudiaby D; Diop OM; Dia N; Diallo A; Ortiz JR; Diop D; Lewis KDC; Lafond KE; Widdowson MA; Victor JC; Neuzil KM
Vaccine; 2020 Nov; 38(47):7526-7532. PubMed ID: 33012603
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.
Gorse GJ; Grimes S; Buck H; Mulla H; White P; Hill H; May J; Frey SE; Blackburn P
Vaccine; 2022 Feb; 40(9):1271-1281. PubMed ID: 35125219
[TBL] [Abstract][Full Text] [Related]
19. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season.
Ganczak M; Dubiel P; Drozd-Dąbrowska M; Hallmann-Szelińska E; Szymański K; Brydak LB
Int J Environ Res Public Health; 2019 Nov; 16(22):. PubMed ID: 31739554
[TBL] [Abstract][Full Text] [Related]
20. A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk.
Yang JR; Cheng CY; Chen CY; Lin CH; Kuo CY; Huang HY; Wu FT; Yang YC; Wu CY; Liu MT; Hsiao PW
Antiviral Res; 2017 Apr; 140():62-75. PubMed ID: 28093338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
